Overview
The company develops lightweight, controllable AI protein design models to reduce the difficulty, development time, and cost of new synthetic biological products and drugs
Funding
Amounts as reported; USD estimates shown only when they matchListed 5 funding records. Latest funding: RMB 10M (Angel), Sep 3, 2025.
4 listed records lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Aug 18, 2026 | Undisclosed · Pre-Series A | 上海千钧策咨询管理合伙企业（有限合伙） | No source link |
Evidence Tushenzhihe completes Pre-Series A financingOn 2026-08-18, according to Xiniu Data, Tushenzhihe completed Pre-Series A financing for an undisclosed amount. Investors were Shanghai Qianjunce Consulting Management Partnership (Limited Partnership). The company is an AI protein design services provider. Translated source brief, not a quotation. Check the original before citing. Sources · 0
| |||
| Jul 31, 2026 | Undisclosed · Equity transfer | 上海聚超晗管理咨询合伙企业（有限合伙） | No source link |
Evidence Tushenzhihe raises an undisclosed amount in equity transferOn 2026-07-31, according to Xiniu Data, Tushenzhihe completed equity transfer for an undisclosed amount. Investors were Shanghai Juchaohan Management Consulting Partnership (Limited Partnership). The company is an AI protein design services provider. Translated source brief, not a quotation. Check the original before citing. Sources · 0
| |||
| Sep 3, 2025 | RMB 10M ≈ $1.43M · Angel | 上海天使会, 诚美资本 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
| Dec 31, 2024 | Undisclosed · Angel | 上海艾特海浦, 锡创投 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
| Feb 29, 2024 | Millions of RMB · Angel | 无锡光子芯谷, 诚美资本 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
Select ▸ on a row to see its source brief and links.
Valuation
Amounts as reported; USD estimates shown only when they matchListed 5 valuation records.
No chartable valuation estimates yet.
5 listed records lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Aug 18, 2026 | — · Pre-Series A | 上海千钧策咨询管理合伙企业（有限合伙） | No source link |
Evidence Tushenzhihe completes Pre-Series A financingOn 2026-08-18, according to Xiniu Data, Tushenzhihe completed Pre-Series A financing for an undisclosed amount. Investors were Shanghai Qianjunce Consulting Management Partnership (Limited Partnership). The company is an AI protein design services provider. Translated source brief, not a quotation. Check the original before citing. Sources · 0
| |||
| Jul 31, 2026 | — · Equity transfer | 上海聚超晗管理咨询合伙企业（有限合伙） | No source link |
Evidence Tushenzhihe raises an undisclosed amount in equity transferOn 2026-07-31, according to Xiniu Data, Tushenzhihe completed equity transfer for an undisclosed amount. Investors were Shanghai Juchaohan Management Consulting Partnership (Limited Partnership). The company is an AI protein design services provider. Translated source brief, not a quotation. Check the original before citing. Sources · 0
| |||
| Sep 3, 2025 | — · Angel | 上海天使会, 诚美资本 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
| Dec 31, 2024 | — · Angel | 上海艾特海浦, 锡创投 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
| Feb 29, 2024 | — · Angel | 无锡光子芯谷, 诚美资本 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
Select ▸ on a row to see its source brief and links.
Revenue
Amounts as reported; USD estimates shown only when they matchNo revenue records are listed yet.
No revenue rows to list.
Team, products & investors
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
公司致力于开发轻量、可控的人工智能蛋白质设计模型。降低生物科技领域中开发新合成生物产品和新药的难度、周期和成本